Omeros shares are trading lower after the company announced it will discontinue the ARTEMIS-IGAN trial, which did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo.
Portfolio Pulse from Benzinga Newsdesk
Omeros Corporation announced the discontinuation of the ARTEMIS-IGAN trial due to its failure to reach statistical significance on the primary endpoint of reduction in proteinuria. This has led to a decrease in the company's share price.
October 16, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Omeros Corporation's shares are trading lower after the company announced the discontinuation of the ARTEMIS-IGAN trial, which did not meet its primary endpoint.
The discontinuation of the ARTEMIS-IGAN trial, which was a significant part of Omeros Corporation's product pipeline, has negatively impacted investor sentiment. This has led to a decrease in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100